AbbVie stock heads into the open after a 1.6% gain
Published on 09/11/2026 at 03:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie stock closed at USD 254.99 on the New York Stock Exchange on September 10, 2026, up 1.6% from the previous USD 250.91 close.
September 10, 2026 in numbers
AbbVie Inc. (ISIN US00287Y1091, NYSE: ABBV) finished the September 10, 2026 session at USD 254.99 on the New York Stock Exchange, gaining 1.6% from the prior USD 250.91 close, with the latest exchange data indicating an intraday high around USD 255.31 and trading within a range that kept the close between the day’s low and high levels. The move left the shares within a documented 52-week span between USD 190.75 and USD 267.47, keeping the close closer to the upper half of that range and framing the recent strength against the longer term band. The most recent prior close of USD 250.91 is also cited in market commentary that describes AbbVie as modestly overvalued on selected valuation models at that level, underscoring that the latest gain pushed the stock slightly further above that earlier reference price.
According to MarketBeat, AbbVie shares traded as high as USD 255.31 during the September 10, 2026 session and last changed hands at USD 254.99, marking the 1.6% advance versus the USD 250.91 prior close and reflecting support from both clinical and analyst developments. In the same context, Benzinga reported on September 10, 2026 that HSBC maintained its buy rating on AbbVie and raised its price target to USD 315, a move that contributed to the upbeat tone around the shares. Additional commentary from Ad-hoc-news highlighted positive Phase 3 atogepant data in menstrual migraine alongside the higher HSBC target as factors supporting AbbVie’s share price near USD 251 during the day, reinforcing the role of both pipeline progress and analyst support in the latest session.
Dividend and analyst focus today
Looking at today, dividend news and analyst commentary remain relevant for AbbVie. As StockTitan reported on September 10, 2026, AbbVie declared a quarterly cash dividend of USD 1.73 per share, a decision that keeps income considerations in focus for investors ahead of today’s US session. The same dividend announcement is echoed in a dedicated dividend news item that cites the USD 250.91 stock price used in that context and the 52-week low and high of USD 190.75 and USD 267.47, underscoring that the payout decision comes while the shares are trading well above the lower end of their documented one-year range. Together with the HSBC price target increase to USD 315 reported on September 10, 2026, these developments ensure that both cash return expectations and longer term valuation views are central points of attention for AbbVie stock today as investors prepare for the next New York Stock Exchange session.
